Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog

 
• By Chloe Kent

Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.

Insulin vial with syringe
The market for biosimilar insulins is heating up in the US • Source: Alamy

Non-profit generics company Civica has entered into a co-development and commercial agreement with Indian biopharmaceutical manufacturer GeneSys Biologics, which will allow it to manufacture and distribute insulins for the US at significantly lower prices than those currently on the market.

The availability of affordable insulins, the company says, will benefit people with diabetes “who have been forced to choose between life sustaining medicines and living expenses, particularly those uninsured or

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products